CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01914159
NCT01914159Phase 2Completed
CompareCT.gov

Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

University Hospital, Bonn·interventional·Posted Aug 1, 2013·Updated Aug 15, 2019

In Brief

A Phase 2 clinical trial evaluating Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany) for Age Related Macular Degeneration. Completed, enrolled 24 participants across 3 sites.

Detailed Summary

The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 1, 2013
Enrollment StartFeb 1, 2013
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.9 years ago

Interventions

Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)drug

Monthly intravitreal injections